Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ReVas Inc.

This article was originally published in Start Up

Executive Summary

ReVas Inc. believes that vasectomy would be a more desirable form of permanent birth control if men knew that the procedure could be easily reversed. The company aims to develop such a method, inserting a nylon stent into the vas deferens to prevent sperm passage, with a portion left outside the vas for venting and to facilitate removal.

You may also be interested in...



Permanent Contraception

Given the huge impact that having a baby has on every aspect of a woman's life--and that of her mate--it's small wonder that a growing number of companies are aiming to offer Baby Boomers improved contraceptive choices. Some are developing devices to make the widely performed tubal ligation surgery, which renders women sterile, less invasive, more convenient and safer than it has been to date. At least one firm hopes to give men a chance to participate in family planning via reversible vasectomization.

Two Korean Pharmas Vie For Wins In High-Need Gout Space

Based on promising Phase II data, two companies in South Korea are moving ahead with late-stage development in the gout space, with JW Pharmaceutical getting approvals to begin a multinational Phase III program for epaminurad, while LG Chem has recently submitting an application for a new Phase III trial with its contender tigulixostat.

US FDA Guidance Aims To Tackle Challenges In Multi-Endpoint Trials

Final guidance targets the ‘multiplicity problem.’ At about half the length of the 2017 draft, the final removes some sections, truncates other and drops several examples.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT037143

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel